 Anna Bruckner
Concepts (433)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epidermolysis Bullosa | 28 | 2023 | 41 | 7.590 |
Why?
| | Hemangioma | 9 | 2016 | 41 | 2.800 |
Why?
| | Dermatology | 6 | 2023 | 86 | 2.510 |
Why?
| | Epidermolysis Bullosa Dystrophica | 12 | 2023 | 21 | 1.960 |
Why?
| | Skin Neoplasms | 12 | 2024 | 761 | 1.910 |
Why?
| | Acne Vulgaris | 2 | 2022 | 20 | 1.250 |
Why?
| | Skin | 8 | 2020 | 662 | 1.110 |
Why?
| | Lymphatic Abnormalities | 2 | 2014 | 18 | 0.860 |
Why?
| | Ichthyosis, Lamellar | 3 | 2022 | 10 | 0.810 |
Why?
| | Gentamicins | 1 | 2022 | 43 | 0.800 |
Why?
| | Humans | 95 | 2024 | 115587 | 0.740 |
Why?
| | Chilblains | 1 | 2020 | 2 | 0.740 |
Why?
| | Alopecia | 2 | 2012 | 28 | 0.730 |
Why?
| | Betacoronavirus | 2 | 2020 | 254 | 0.730 |
Why?
| | Child | 41 | 2024 | 18488 | 0.720 |
Why?
| | Dermatitis, Allergic Contact | 4 | 2002 | 63 | 0.710 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2020 | 32 | 0.690 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2020 | 34 | 0.690 |
Why?
| | Severity of Illness Index | 7 | 2022 | 2578 | 0.680 |
Why?
| | Isotretinoin | 2 | 2022 | 22 | 0.660 |
Why?
| | Exanthema | 1 | 2020 | 77 | 0.660 |
Why?
| | Diagnosis, Differential | 13 | 2015 | 1357 | 0.660 |
Why?
| | Pandemics | 4 | 2023 | 1334 | 0.640 |
Why?
| | Infant | 23 | 2022 | 7979 | 0.640 |
Why?
| | Skin Diseases | 3 | 2011 | 124 | 0.630 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 344 | 0.630 |
Why?
| | Coronavirus Infections | 2 | 2020 | 336 | 0.630 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 140 | 0.620 |
Why?
| | Mandelic Acids | 1 | 2018 | 1 | 0.620 |
Why?
| | Parasympatholytics | 1 | 2018 | 13 | 0.610 |
Why?
| | Hyperhidrosis | 1 | 2018 | 5 | 0.610 |
Why?
| | GTP-Binding Protein alpha Subunits | 2 | 2016 | 12 | 0.590 |
Why?
| | Education, Distance | 1 | 2017 | 39 | 0.580 |
Why?
| | Telemedicine | 2 | 2023 | 667 | 0.570 |
Why?
| | Dermatitis, Atopic | 2 | 2017 | 310 | 0.560 |
Why?
| | Vascular Neoplasms | 2 | 2016 | 16 | 0.560 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2016 | 52 | 0.530 |
Why?
| | Histiocytosis | 1 | 2015 | 8 | 0.520 |
Why?
| | Epidermolysis Bullosa, Junctional | 3 | 2021 | 3 | 0.520 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2015 | 25 | 0.520 |
Why?
| | Alopecia Areata | 2 | 2022 | 9 | 0.500 |
Why?
| | Rare Diseases | 1 | 2015 | 89 | 0.490 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2015 | 35 | 0.490 |
Why?
| | Nevus, Pigmented | 1 | 2015 | 34 | 0.490 |
Why?
| | Anemia | 5 | 2023 | 144 | 0.490 |
Why?
| | Thrombocytopenia | 2 | 2016 | 175 | 0.490 |
Why?
| | Endothelium, Lymphatic | 1 | 2014 | 12 | 0.470 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2014 | 22 | 0.470 |
Why?
| | Sweat Gland Neoplasms | 2 | 2011 | 6 | 0.470 |
Why?
| | Hydrops Fetalis | 1 | 2014 | 13 | 0.460 |
Why?
| | Male | 41 | 2024 | 55949 | 0.460 |
Why?
| | Drug Eruptions | 1 | 2013 | 26 | 0.460 |
Why?
| | Epidermolysis Bullosa Simplex | 3 | 2023 | 9 | 0.450 |
Why?
| | Child, Preschool | 17 | 2020 | 9133 | 0.440 |
Why?
| | Propranolol | 2 | 2011 | 53 | 0.440 |
Why?
| | Female | 38 | 2022 | 59913 | 0.440 |
Why?
| | Dermatologic Agents | 1 | 2013 | 57 | 0.440 |
Why?
| | Infant, Newborn | 13 | 2016 | 5077 | 0.430 |
Why?
| | Adolescent | 20 | 2022 | 17889 | 0.430 |
Why?
| | Hemangioendothelioma | 1 | 2012 | 12 | 0.420 |
Why?
| | Kasabach-Merritt Syndrome | 1 | 2012 | 4 | 0.420 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2013 | 138 | 0.420 |
Why?
| | Internship and Residency | 2 | 2022 | 951 | 0.410 |
Why?
| | Langer-Giedion Syndrome | 1 | 2012 | 2 | 0.410 |
Why?
| | Hair Diseases | 1 | 2012 | 6 | 0.410 |
Why?
| | Clinical Competence | 2 | 2022 | 912 | 0.400 |
Why?
| | Bone Demineralization, Pathologic | 1 | 2011 | 2 | 0.400 |
Why?
| | Sarcoma, Kaposi | 1 | 2012 | 69 | 0.400 |
Why?
| | Phosphodiesterase 5 Inhibitors | 1 | 2012 | 36 | 0.400 |
Why?
| | Ichthyosis | 2 | 2022 | 12 | 0.390 |
Why?
| | Calcification, Physiologic | 1 | 2011 | 35 | 0.390 |
Why?
| | Bone Diseases, Metabolic | 2 | 2011 | 53 | 0.380 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2014 | 420 | 0.380 |
Why?
| | Sulfones | 1 | 2012 | 98 | 0.380 |
Why?
| | Microscopy, Fluorescence | 1 | 2013 | 402 | 0.380 |
Why?
| | Bone Density | 2 | 2011 | 432 | 0.370 |
Why?
| | 2-Propanol | 1 | 2011 | 21 | 0.370 |
Why?
| | Hyperpigmentation | 1 | 2011 | 11 | 0.370 |
Why?
| | Facial Dermatoses | 2 | 2010 | 14 | 0.370 |
Why?
| | Facial Neoplasms | 1 | 2011 | 17 | 0.370 |
Why?
| | Dermis | 2 | 2011 | 30 | 0.370 |
Why?
| | Gene Deletion | 1 | 2012 | 355 | 0.370 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2125 | 0.360 |
Why?
| | Solvents | 1 | 2011 | 108 | 0.360 |
Why?
| | Ferrochelatase | 1 | 2010 | 1 | 0.360 |
Why?
| | Porphyria, Erythropoietic | 1 | 2010 | 2 | 0.360 |
Why?
| | Tumor Burden | 1 | 2011 | 261 | 0.360 |
Why?
| | Desmoplakins | 1 | 2010 | 19 | 0.350 |
Why?
| | Cardiomyopathy, Hypertrophic, Familial | 1 | 2010 | 16 | 0.350 |
Why?
| | Laryngeal Neoplasms | 1 | 2010 | 27 | 0.350 |
Why?
| | Xanthomatosis | 1 | 2009 | 11 | 0.350 |
Why?
| | Mediastinal Neoplasms | 1 | 2010 | 32 | 0.340 |
Why?
| | Piperazines | 1 | 2012 | 314 | 0.340 |
Why?
| | Granuloma | 1 | 2010 | 85 | 0.340 |
Why?
| | Immunohistochemistry | 5 | 2019 | 1642 | 0.340 |
Why?
| | Consensus | 4 | 2023 | 532 | 0.330 |
Why?
| | Carcinoma | 1 | 2011 | 200 | 0.330 |
Why?
| | Young Adult | 11 | 2020 | 10470 | 0.320 |
Why?
| | Parakeratosis | 1 | 2008 | 1 | 0.320 |
Why?
| | Pruritus | 3 | 2014 | 60 | 0.310 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2010 | 293 | 0.300 |
Why?
| | Canada | 3 | 2020 | 335 | 0.300 |
Why?
| | Self-Help Groups | 1 | 2007 | 30 | 0.290 |
Why?
| | Dermatitis, Exfoliative | 1 | 2006 | 4 | 0.290 |
Why?
| | Hand Dermatoses | 1 | 2006 | 8 | 0.280 |
Why?
| | Immunoglobulin A | 3 | 2018 | 173 | 0.280 |
Why?
| | Ethics, Medical | 1 | 2007 | 70 | 0.280 |
Why?
| | Prospective Studies | 4 | 2022 | 6264 | 0.270 |
Why?
| | Mutation | 5 | 2018 | 3364 | 0.260 |
Why?
| | Pemphigus | 1 | 2005 | 8 | 0.260 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2022 | 577 | 0.260 |
Why?
| | Practice Patterns, Physicians' | 1 | 2014 | 1180 | 0.250 |
Why?
| | Hamartoma | 1 | 2005 | 21 | 0.250 |
Why?
| | Biopsy, Needle | 3 | 2019 | 183 | 0.240 |
Why?
| | Observer Variation | 4 | 2022 | 297 | 0.240 |
Why?
| | Incontinentia Pigmenti | 1 | 2004 | 3 | 0.240 |
Why?
| | Transcription Factors | 1 | 2012 | 1528 | 0.240 |
Why?
| | Wound Healing | 2 | 2022 | 257 | 0.230 |
Why?
| | Pediatrics | 1 | 2012 | 986 | 0.230 |
Why?
| | Aspirin | 1 | 2006 | 326 | 0.230 |
Why?
| | Sarcoma, Clear Cell | 1 | 2024 | 8 | 0.230 |
Why?
| | Biopsy | 3 | 2015 | 1056 | 0.230 |
Why?
| | Collagen Type VII | 2 | 2021 | 13 | 0.230 |
Why?
| | North America | 3 | 2021 | 261 | 0.230 |
Why?
| | Immunoglobulin G | 3 | 2018 | 781 | 0.230 |
Why?
| | Scalp | 1 | 2024 | 29 | 0.230 |
Why?
| | Water | 1 | 2006 | 412 | 0.220 |
Why?
| | Decision Support Techniques | 1 | 2007 | 353 | 0.220 |
Why?
| | Administration, Topical | 3 | 2020 | 137 | 0.220 |
Why?
| | Privacy | 1 | 2023 | 29 | 0.220 |
Why?
| | Retrospective Studies | 12 | 2023 | 12608 | 0.220 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2006 | 399 | 0.220 |
Why?
| | Triterpenes | 1 | 2023 | 17 | 0.210 |
Why?
| | Confidentiality | 1 | 2023 | 67 | 0.210 |
Why?
| | Skin Care | 2 | 2020 | 18 | 0.210 |
Why?
| | Cohort Studies | 4 | 2022 | 4944 | 0.200 |
Why?
| | Rhabdomyosarcoma, Embryonal | 1 | 2022 | 16 | 0.200 |
Why?
| | Competency-Based Education | 1 | 2022 | 66 | 0.200 |
Why?
| | Anesthetics | 1 | 2022 | 57 | 0.200 |
Why?
| | Jews | 1 | 2021 | 19 | 0.200 |
Why?
| | Administration, Intravenous | 1 | 2022 | 126 | 0.190 |
Why?
| | Rhabdomyosarcoma | 1 | 2022 | 52 | 0.190 |
Why?
| | Fatal Outcome | 2 | 2014 | 286 | 0.190 |
Why?
| | Follow-Up Studies | 4 | 2019 | 4440 | 0.190 |
Why?
| | Adrenal Cortex Hormones | 2 | 2014 | 509 | 0.190 |
Why?
| | Pseudomonas aeruginosa | 1 | 2023 | 301 | 0.190 |
Why?
| | Treatment Outcome | 7 | 2018 | 9159 | 0.190 |
Why?
| | Palliative Care | 1 | 2007 | 642 | 0.190 |
Why?
| | Absorptiometry, Photon | 2 | 2011 | 221 | 0.180 |
Why?
| | Toes | 1 | 2020 | 26 | 0.180 |
Why?
| | NF-kappa B | 1 | 2004 | 639 | 0.180 |
Why?
| | Iron | 3 | 2023 | 235 | 0.180 |
Why?
| | Mycoplasma pneumoniae | 1 | 2020 | 32 | 0.170 |
Why?
| | Detergents | 1 | 2020 | 41 | 0.170 |
Why?
| | Kidney Neoplasms | 1 | 2024 | 326 | 0.170 |
Why?
| | Mouth Diseases | 2 | 2013 | 38 | 0.170 |
Why?
| | Mouth Mucosa | 2 | 2013 | 79 | 0.170 |
Why?
| | Prenatal Diagnosis | 2 | 2014 | 167 | 0.170 |
Why?
| | Chronic Pain | 1 | 2022 | 210 | 0.160 |
Why?
| | APOBEC Deaminases | 1 | 2018 | 4 | 0.160 |
Why?
| | Adult | 13 | 2023 | 30718 | 0.160 |
Why?
| | Administration, Oral | 2 | 2012 | 734 | 0.160 |
Why?
| | Cytosine Deaminase | 1 | 2018 | 14 | 0.160 |
Why?
| | Linear IgA Bullous Dermatosis | 1 | 2018 | 1 | 0.160 |
Why?
| | Education, Medical, Graduate | 1 | 2022 | 376 | 0.160 |
Why?
| | Esophageal Stenosis | 1 | 2018 | 44 | 0.160 |
Why?
| | Dilatation | 1 | 2018 | 59 | 0.160 |
Why?
| | Fluoroscopy | 1 | 2018 | 141 | 0.150 |
Why?
| | Age Distribution | 1 | 2019 | 341 | 0.150 |
Why?
| | Patient Satisfaction | 1 | 2022 | 585 | 0.150 |
Why?
| | Quality of Life | 2 | 2020 | 2385 | 0.150 |
Why?
| | Sex Distribution | 1 | 2019 | 337 | 0.150 |
Why?
| | Cost of Illness | 1 | 2020 | 257 | 0.150 |
Why?
| | Databases, Factual | 2 | 2020 | 1138 | 0.150 |
Why?
| | Esophagoscopy | 1 | 2018 | 183 | 0.140 |
Why?
| | Staphylococcal Infections | 1 | 2020 | 337 | 0.140 |
Why?
| | GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2016 | 14 | 0.140 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2016 | 30 | 0.140 |
Why?
| | Incidence | 2 | 2022 | 2335 | 0.140 |
Why?
| | Risk Assessment | 3 | 2019 | 2987 | 0.130 |
Why?
| | Patient Care Team | 1 | 2020 | 521 | 0.130 |
Why?
| | Survival Analysis | 1 | 2019 | 1219 | 0.130 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2022 | 538 | 0.130 |
Why?
| | Clobetasol | 1 | 2015 | 4 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2022 | 4665 | 0.130 |
Why?
| | Pachyonychia Congenita | 1 | 2015 | 4 | 0.130 |
Why?
| | United States | 4 | 2021 | 12295 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2016 | 277 | 0.120 |
Why?
| | Middle Aged | 7 | 2020 | 26999 | 0.120 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 275 | 0.120 |
Why?
| | Keratins | 1 | 2015 | 176 | 0.120 |
Why?
| | Transplantation Conditioning | 1 | 2015 | 150 | 0.120 |
Why?
| | Genes, Recessive | 2 | 2021 | 72 | 0.120 |
Why?
| | Disease Progression | 2 | 2019 | 2418 | 0.120 |
Why?
| | Antigens, CD34 | 1 | 2014 | 90 | 0.120 |
Why?
| | Prednisolone | 2 | 2013 | 77 | 0.110 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1718 | 0.110 |
Why?
| | Transcriptome | 2 | 2018 | 736 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 3 | 2014 | 448 | 0.110 |
Why?
| | Caregivers | 1 | 2020 | 713 | 0.110 |
Why?
| | Pilot Projects | 1 | 2018 | 1377 | 0.110 |
Why?
| | Pemphigoid, Bullous | 1 | 2013 | 7 | 0.110 |
Why?
| | Remission, Spontaneous | 1 | 2012 | 37 | 0.110 |
Why?
| | Fluorescent Antibody Technique | 2 | 2021 | 398 | 0.110 |
Why?
| | Skin Diseases, Papulosquamous | 1 | 2012 | 1 | 0.110 |
Why?
| | Erythema | 3 | 2022 | 25 | 0.100 |
Why?
| | Prednisone | 2 | 2005 | 232 | 0.100 |
Why?
| | Oropharynx | 1 | 2012 | 36 | 0.100 |
Why?
| | Sildenafil Citrate | 1 | 2012 | 58 | 0.100 |
Why?
| | Panniculitis | 1 | 2011 | 2 | 0.100 |
Why?
| | Actins | 1 | 2014 | 383 | 0.100 |
Why?
| | Nose | 1 | 2012 | 56 | 0.100 |
Why?
| | Carcinoma, Verrucous | 1 | 2011 | 1 | 0.100 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1484 | 0.100 |
Why?
| | Blood Sedimentation | 1 | 2011 | 34 | 0.100 |
Why?
| | Age Determination by Skeleton | 1 | 2011 | 18 | 0.100 |
Why?
| | Fingers | 1 | 2012 | 83 | 0.100 |
Why?
| | Fractures, Compression | 1 | 2011 | 18 | 0.100 |
Why?
| | Dwarfism | 1 | 2011 | 15 | 0.100 |
Why?
| | Calcifediol | 1 | 2011 | 29 | 0.100 |
Why?
| | Subcutaneous Fat | 1 | 2011 | 71 | 0.090 |
Why?
| | Vincristine | 1 | 2011 | 96 | 0.090 |
Why?
| | Purines | 1 | 2012 | 159 | 0.090 |
Why?
| | Mobility Limitation | 1 | 2011 | 60 | 0.090 |
Why?
| | RNA, Messenger | 2 | 2015 | 2574 | 0.090 |
Why?
| | Body Size | 1 | 2011 | 92 | 0.090 |
Why?
| | Body Height | 1 | 2011 | 180 | 0.090 |
Why?
| | Darier Disease | 1 | 2010 | 2 | 0.090 |
Why?
| | Hypothermia, Induced | 1 | 2011 | 69 | 0.090 |
Why?
| | Autoantibodies | 1 | 2018 | 1360 | 0.090 |
Why?
| | Glucocorticoids | 1 | 2015 | 552 | 0.090 |
Why?
| | Serum Albumin | 1 | 2011 | 135 | 0.090 |
Why?
| | Drug Therapy, Combination | 2 | 2011 | 962 | 0.090 |
Why?
| | Steroids | 1 | 2011 | 147 | 0.090 |
Why?
| | Spinal Fractures | 1 | 2011 | 78 | 0.090 |
Why?
| | Sequence Analysis, DNA | 2 | 2010 | 732 | 0.090 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2010 | 36 | 0.090 |
Why?
| | Porphyrins | 1 | 2010 | 17 | 0.090 |
Why?
| | Patch Tests | 2 | 2001 | 52 | 0.090 |
Why?
| | Clarithromycin | 1 | 2010 | 25 | 0.090 |
Why?
| | Consanguinity | 1 | 2010 | 47 | 0.090 |
Why?
| | Erythromycin | 1 | 2010 | 24 | 0.090 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2015 | 519 | 0.090 |
Why?
| | Foam Cells | 1 | 2009 | 13 | 0.090 |
Why?
| | Infant, Newborn, Diseases | 1 | 2011 | 103 | 0.090 |
Why?
| | Ointments | 2 | 2023 | 23 | 0.090 |
Why?
| | Porokeratosis | 1 | 2009 | 1 | 0.090 |
Why?
| | Nevus, Intradermal | 1 | 2009 | 3 | 0.090 |
Why?
| | Keratosis | 1 | 2009 | 13 | 0.090 |
Why?
| | Sequence Deletion | 1 | 2010 | 167 | 0.080 |
Why?
| | Staining and Labeling | 1 | 2010 | 139 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1198 | 0.080 |
Why?
| | Basement Membrane | 2 | 2007 | 29 | 0.080 |
Why?
| | Epidermodysplasia Verruciformis | 1 | 2009 | 1 | 0.080 |
Why?
| | Radiography | 1 | 2012 | 826 | 0.080 |
Why?
| | Respiratory Sounds | 1 | 2010 | 111 | 0.080 |
Why?
| | Lumbar Vertebrae | 1 | 2011 | 217 | 0.080 |
Why?
| | Hemoglobins | 1 | 2011 | 312 | 0.080 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2011 | 281 | 0.080 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2010 | 139 | 0.080 |
Why?
| | C-Reactive Protein | 1 | 2011 | 364 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2023 | 1660 | 0.080 |
Why?
| | Dapsone | 2 | 2005 | 5 | 0.080 |
Why?
| | Diaper Rash | 1 | 2008 | 4 | 0.080 |
Why?
| | Blister | 3 | 2013 | 43 | 0.080 |
Why?
| | Phenotype | 2 | 2021 | 2829 | 0.080 |
Why?
| | Immune System Diseases | 1 | 2008 | 35 | 0.080 |
Why?
| | Weight Gain | 1 | 2011 | 453 | 0.080 |
Why?
| | Hair | 1 | 2008 | 66 | 0.080 |
Why?
| | Biomedical Research | 1 | 2014 | 588 | 0.080 |
Why?
| | Psychophysiologic Disorders | 1 | 2007 | 10 | 0.080 |
Why?
| | Airway Obstruction | 1 | 2010 | 168 | 0.070 |
Why?
| | Endothelium, Vascular | 1 | 2014 | 845 | 0.070 |
Why?
| | Models, Theoretical | 1 | 2011 | 519 | 0.070 |
Why?
| | Anti-Anxiety Agents | 1 | 2007 | 44 | 0.070 |
Why?
| | Euthanasia, Passive | 1 | 2007 | 2 | 0.070 |
Why?
| | Ethics Committees | 1 | 2007 | 3 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2011 | 521 | 0.070 |
Why?
| | Hematinics | 1 | 2006 | 18 | 0.070 |
Why?
| | Androgens | 1 | 2008 | 165 | 0.070 |
Why?
| | Patient Advocacy | 1 | 2007 | 66 | 0.070 |
Why?
| | Interdisciplinary Communication | 2 | 2020 | 185 | 0.070 |
Why?
| | Aged | 3 | 2020 | 19251 | 0.070 |
Why?
| | Ferric Compounds | 1 | 2006 | 40 | 0.070 |
Why?
| | Erythropoietin | 1 | 2006 | 72 | 0.070 |
Why?
| | Antidepressive Agents | 1 | 2007 | 195 | 0.070 |
Why?
| | California | 1 | 2007 | 367 | 0.070 |
Why?
| | Physicians | 1 | 2014 | 776 | 0.070 |
Why?
| | Genetic Therapy | 1 | 2007 | 260 | 0.060 |
Why?
| | Antipsychotic Agents | 1 | 2007 | 183 | 0.060 |
Why?
| | Professional-Family Relations | 1 | 2007 | 138 | 0.060 |
Why?
| | Desmoglein 3 | 1 | 2005 | 17 | 0.060 |
Why?
| | Skin Diseases, Vesiculobullous | 1 | 2005 | 17 | 0.060 |
Why?
| | Colonic Diseases | 1 | 2005 | 25 | 0.060 |
Why?
| | Social Environment | 1 | 2007 | 286 | 0.060 |
Why?
| | Calcium | 1 | 2011 | 1103 | 0.060 |
Why?
| | Immunosuppressive Agents | 2 | 2015 | 666 | 0.060 |
Why?
| | Cellulitis | 1 | 2005 | 46 | 0.060 |
Why?
| | Reproducibility of Results | 3 | 2022 | 2800 | 0.060 |
Why?
| | Dermatitis Herpetiformis | 1 | 2004 | 1 | 0.060 |
Why?
| | Epidermis | 1 | 2005 | 149 | 0.060 |
Why?
| | Pregnancy | 2 | 2014 | 5548 | 0.060 |
Why?
| | Neutrophils | 1 | 2009 | 1172 | 0.060 |
Why?
| | Urticaria | 1 | 2004 | 51 | 0.060 |
Why?
| | Anthraquinones | 1 | 2023 | 9 | 0.060 |
Why?
| | Social Support | 1 | 2007 | 537 | 0.060 |
Why?
| | Excipients | 1 | 2023 | 49 | 0.050 |
Why?
| | Eosinophilia | 1 | 2005 | 186 | 0.050 |
Why?
| | Betula | 1 | 2023 | 3 | 0.050 |
Why?
| | Family | 1 | 2007 | 594 | 0.050 |
Why?
| | Antibodies | 1 | 2005 | 374 | 0.050 |
Why?
| | Catastrophization | 1 | 2022 | 8 | 0.050 |
Why?
| | Algorithms | 2 | 2007 | 1490 | 0.050 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 795 | 0.050 |
Why?
| | Communicable Disease Control | 1 | 2023 | 66 | 0.050 |
Why?
| | Histamine H1 Antagonists | 1 | 2002 | 33 | 0.050 |
Why?
| | Professionalism | 1 | 2022 | 14 | 0.050 |
Why?
| | Prevalence | 2 | 2022 | 2264 | 0.050 |
Why?
| | Mucous Membrane | 2 | 2014 | 109 | 0.050 |
Why?
| | Autoantigens | 1 | 2005 | 398 | 0.050 |
Why?
| | Atrophy | 2 | 2013 | 152 | 0.050 |
Why?
| | Accreditation | 1 | 2022 | 78 | 0.050 |
Why?
| | Germ Cells | 1 | 2022 | 61 | 0.050 |
Why?
| | Chile | 1 | 2021 | 16 | 0.050 |
Why?
| | Social Class | 1 | 2023 | 210 | 0.050 |
Why?
| | Colombia | 1 | 2021 | 36 | 0.050 |
Why?
| | Photography | 1 | 2022 | 89 | 0.050 |
Why?
| | Tertiary Care Centers | 1 | 2022 | 127 | 0.050 |
Why?
| | Parents | 2 | 2022 | 1205 | 0.050 |
Why?
| | Educational Status | 1 | 2023 | 413 | 0.050 |
Why?
| | Blood Protein Electrophoresis | 1 | 1981 | 7 | 0.050 |
Why?
| | Information Dissemination | 1 | 2023 | 193 | 0.050 |
Why?
| | Nephelometry and Turbidimetry | 1 | 1981 | 16 | 0.050 |
Why?
| | Mexico | 1 | 2021 | 163 | 0.050 |
Why?
| | Mupirocin | 1 | 2020 | 7 | 0.050 |
Why?
| | Language | 1 | 2023 | 258 | 0.050 |
Why?
| | Retinoids | 1 | 2020 | 31 | 0.050 |
Why?
| | Inflammation | 1 | 2011 | 2499 | 0.050 |
Why?
| | Immunoglobulins | 1 | 1981 | 147 | 0.040 |
Why?
| | Minority Groups | 1 | 2022 | 230 | 0.040 |
Why?
| | Cosmetics | 1 | 2020 | 7 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3069 | 0.040 |
Why?
| | Desmocollins | 1 | 2018 | 2 | 0.040 |
Why?
| | Desmogleins | 1 | 2018 | 5 | 0.040 |
Why?
| | Mutation Rate | 1 | 2018 | 26 | 0.040 |
Why?
| | Age of Onset | 1 | 2000 | 450 | 0.040 |
Why?
| | Mutagenesis | 1 | 2018 | 170 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2018 | 156 | 0.040 |
Why?
| | Health Personnel | 1 | 2023 | 581 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2020 | 385 | 0.040 |
Why?
| | Self Care | 1 | 2020 | 354 | 0.040 |
Why?
| | DNA Repair | 1 | 2018 | 190 | 0.040 |
Why?
| | Keratinocytes | 1 | 2018 | 215 | 0.030 |
Why?
| | Esophagus | 1 | 2018 | 226 | 0.030 |
Why?
| | Age Factors | 2 | 2014 | 2907 | 0.030 |
Why?
| | Melanocytes | 1 | 2016 | 55 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2016 | 90 | 0.030 |
Why?
| | Pain | 2 | 2015 | 712 | 0.030 |
Why?
| | Alemtuzumab | 1 | 2015 | 12 | 0.030 |
Why?
| | Myeloablative Agonists | 1 | 2015 | 21 | 0.030 |
Why?
| | Busulfan | 1 | 2015 | 14 | 0.030 |
Why?
| | Vidarabine | 1 | 2015 | 27 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 844 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2022 | 805 | 0.030 |
Why?
| | Keratin-16 | 1 | 2015 | 2 | 0.030 |
Why?
| | Keratin-6 | 1 | 2015 | 6 | 0.030 |
Why?
| | Skin Cream | 1 | 2014 | 7 | 0.030 |
Why?
| | Keratin-17 | 1 | 2015 | 4 | 0.030 |
Why?
| | Oils | 1 | 2014 | 19 | 0.030 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 59 | 0.030 |
Why?
| | HIV Infections | 1 | 2009 | 2473 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2016 | 350 | 0.030 |
Why?
| | Enzymes | 1 | 2015 | 61 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2016 | 793 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2016 | 400 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2015 | 397 | 0.030 |
Why?
| | Oral Medicine | 1 | 2013 | 1 | 0.030 |
Why?
| | Lip Diseases | 1 | 2013 | 6 | 0.030 |
Why?
| | Tongue Diseases | 1 | 2013 | 8 | 0.030 |
Why?
| | Risk Factors | 1 | 2006 | 8697 | 0.030 |
Why?
| | Palate | 1 | 2013 | 27 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1147 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1405 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 746 | 0.030 |
Why?
| | Ankyloglossia | 1 | 2012 | 1 | 0.030 |
Why?
| | Microstomia | 1 | 2012 | 1 | 0.030 |
Why?
| | Mouth Abnormalities | 1 | 2012 | 2 | 0.030 |
Why?
| | Dental Enamel Hypoplasia | 1 | 2012 | 6 | 0.030 |
Why?
| | Down-Regulation | 1 | 2015 | 601 | 0.030 |
Why?
| | Ulcer | 1 | 2012 | 28 | 0.030 |
Why?
| | Cooperative Behavior | 1 | 2014 | 390 | 0.030 |
Why?
| | Cicatrix | 1 | 2012 | 50 | 0.020 |
Why?
| | Back | 1 | 2011 | 10 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 1127 | 0.020 |
Why?
| | Up-Regulation | 1 | 2015 | 820 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 309 | 0.020 |
Why?
| | Therapeutics | 1 | 2011 | 12 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 390 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2015 | 667 | 0.020 |
Why?
| | Necrosis | 1 | 2011 | 210 | 0.020 |
Why?
| | Fibroblasts | 1 | 2015 | 839 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2014 | 497 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2014 | 646 | 0.020 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2011 | 181 | 0.020 |
Why?
| | Elastic Tissue | 1 | 2009 | 7 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2015 | 961 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 4435 | 0.020 |
Why?
| | Hair Follicle | 1 | 2009 | 44 | 0.020 |
Why?
| | Exons | 1 | 2010 | 300 | 0.020 |
Why?
| | Vasodilator Agents | 1 | 2011 | 308 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 372 | 0.020 |
Why?
| | Neck | 1 | 2009 | 84 | 0.020 |
Why?
| | Resuscitation | 1 | 2011 | 247 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2016 | 3914 | 0.020 |
Why?
| | Arm | 1 | 2009 | 105 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2015 | 1536 | 0.020 |
Why?
| | Heart Arrest | 1 | 2011 | 289 | 0.020 |
Why?
| | Preimplantation Diagnosis | 1 | 2007 | 4 | 0.020 |
Why?
| | Skin Diseases, Genetic | 1 | 2007 | 10 | 0.020 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2007 | 37 | 0.020 |
Why?
| | Wound Infection | 1 | 2007 | 30 | 0.020 |
Why?
| | Darbepoetin alfa | 1 | 2006 | 2 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 6417 | 0.020 |
Why?
| | Prognosis | 1 | 2014 | 3339 | 0.020 |
Why?
| | Malnutrition | 1 | 2007 | 62 | 0.020 |
Why?
| | Fetal Diseases | 1 | 2007 | 148 | 0.020 |
Why?
| | Primary Health Care | 1 | 2014 | 1518 | 0.020 |
Why?
| | Syndrome | 1 | 2005 | 339 | 0.010 |
Why?
| | Emergency Service, Hospital | 1 | 2013 | 1829 | 0.010 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 301 | 0.010 |
Why?
| | Animals | 1 | 2002 | 32102 | 0.010 |
Why?
| | Immunoglobulin M | 1 | 1981 | 254 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1598 | 0.010 |
Why?
|
|
Bruckner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|